Decheng Capital as of Sept. 30, 2025
Portfolio Holdings for Decheng Capital
Decheng Capital holds 23 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cg Oncology (CGON) | 44.8 | $257M | 6.4M | 40.28 | |
| Nuvation Bio (NUVB) | 16.8 | $96M | 26M | 3.70 | |
| Upstream Bio (UPB) | 10.8 | $62M | 3.3M | 18.81 | |
| Aardvark Therapeutics (AARD) | 9.1 | $52M | 3.9M | 13.29 | |
| Newamsterdam Pharma Co Nv (NAMS) | 3.3 | $19M | 657k | 28.44 | |
| Merus N V (MRUS) | 3.1 | $18M | 187k | 94.15 | |
| Revolution Medicines (RVMD) | 1.7 | $9.8M | 210k | 46.70 | |
| Lyell Immunopharma | 1.7 | $9.7M | 596k | 16.24 | |
| BeyondSpring SHS (BYSI) | 1.4 | $7.8M | 4.3M | 1.81 | |
| Aclaris Therapeutics (ACRS) | 1.3 | $7.7M | 4.0M | 1.90 | |
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $7.4M | 548k | 13.60 | |
| Equillium (EQ) | 1.1 | $6.4M | 4.4M | 1.43 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.0 | $6.0M | 143k | 41.65 | |
| Krystal Biotech (KRYS) | 1.0 | $5.7M | 32k | 176.53 | |
| Aura Biosciences (AURA) | 0.6 | $3.2M | 516k | 6.18 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.3 | $2.0M | 1.3M | 1.51 | |
| Helix Acquisition Corp | 0.2 | $1.3M | 182k | 7.17 | |
| 4d Molecular Therapeutics In (FDMT) | 0.1 | $806k | 93k | 8.69 | |
| Illumina (ILMN) | 0.1 | $758k | 8.0k | 94.97 | |
| Pyxis Oncology (PYXS) | 0.1 | $726k | 327k | 2.22 | |
| Grail (GRAL) | 0.1 | $573k | 9.7k | 59.13 | |
| Rezolute (RZLT) | 0.1 | $563k | 60k | 9.40 | |
| Nuvation Bio Warrants (NUVB.WS) | 0.0 | $116k | 646k | 0.18 |
